Publish time: 2021-11-12 00:00:00
12A-1080808
TW I841844、PCT
The current drug delivery system for myocardial infarction depends on enhanced permeability and retention (EPR) effect. Due to the lack of long-term EPR effect after infarction, less than 0.1% of the intravenous-injected drugs are retained in the myocardium. Monocytes are recruited to the injury site after myocardial infarction. In this study, we developed a monocyte-specific aptamer-liposome drug delivery system, from which the cardiac protection drugs are carried by monocytes to the injury sites with high specificity and efficacy.
- To enhance the drug delivery efficiency to the heart injury site
- To enhance the drug therapeutic efficacy for heart injury
- For myocardial infarction treatment
- For cardiac ischemia reperfusion injury treatment
Dr. Hsieh, Patrick Ching-Ho, Research Fellow< IBMS
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Monocyte-Specific Aptamers and Uses Thereof for Delivering Therapeutic Agents to Heart